Insulet price target lowered to $330 from $375 at Wells Fargo

Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Insulet to $330 from $375 and keeps an Overweight rating on the shares. The firm notes Insulet reported Q2 sales and EPS that exceeded expectations and raised 2023 sales guidance. Their pipeline remains on track for an eventful 2024, with the launches of O5 outside-U.S., Omnipod Go in the U.S., and continued CGM integration progress.